P2RX7 and neoplasm: The best-characterized receptor for eATP in cancer is P2X7, which is expressed by both immune and tumor cells, promoting cancer growth [4], neovascularization [5], dissemination [6], and release of its ligand ATP [7], as well as activating tumor-eradicating immune responses [8–10].